Q2
BMY — Q2 2026 Financial Report Analysis
BMS Q2 2026 revenue rose 5.7% to $12.97B as Eliquis jumped 22% after a U.S. list-price cut and the Growth Portfolio grew 15%, outrunning Revlimid/Pomalyst generic erosion; GAAP EPS of $1.62 lapped a $1.5B BioNTech charge and 2026 guidance was raised.